

Paper 171-2013

Moving to SAS® Drug Development 4.2

Magnus Mengelbier, Limelogic

ABSTRACT

Life Science organizations have a long investment into business processes, standards, and conventions that make it difficult to simply turn to a new generation of analysis environments. SAS® Drug Development 4.1 integrates many key features found in current analysis environments that are spread across several applications and systems, which need to be monitored and managed accordingly. The paper considers a set of SAS® programs and how the SAS Drug Development repository, workspace, and workflow features support a common business process with all of the associated tools and utilities. The result is a short list of points to consider and some tricks for moving a business process from a PC SAS or SAS server environment to the new release of SAS Drug Development.

No paper was submitted for publication.

CONTACT INFORMATION

Magnus Mengelbier
Limelogic
mmr@limelogic.com

SAS and all other SAS Institute Inc. product or service names are registered trademarks or trademarks of SAS Institute Inc. in the USA and other countries. ® indicates USA registration.

Other brand and product names are trademarks of their respective companies.